000063300 001__ 63300
000063300 005__ 20171129112117.0
000063300 0247_ $$2doi$$a10.1371/journal.pone.0053741
000063300 0248_ $$2sideral$$a81807
000063300 037__ $$aART-2013-81807
000063300 041__ $$aeng
000063300 100__ $$aLorente, L.
000063300 245__ $$aPrognostic Value of Malondialdehyde Serum Levels in Severe Sepsis: A Multicenter Study
000063300 260__ $$c2013
000063300 5060_ $$aAccess copy available to the general public$$fUnrestricted
000063300 5203_ $$aObjective:
The oxidant/antioxidant state in septic patients has only been studied in small series. We wished to determine whether malondialdehyde (MDA) serum levels were associated with severity and 30-day mortality in a large series of patients with sepsis.
Methods:
We performed an observational, prospective, multicenter study in six Spanish Intensive Care Units. Serum levels of MDA were measured in a total of 228 patients (145 survivors and 83 non-survivors) with severe sepsis and 100 healthy controls.
Results:
Serum levels of MDA were higher in severe septic patients than in healthy controls. Non-surviving septic patients had higher MDA values than survivors. MDA serum levels were associated with severity markers (lactic acid, SOFA, APACHE-II) and coagulation indices. Regression analysis showed that MDA serum levels were associated with 30-day survival (Hazard ratio¿=¿1.05; 95% confidence interval¿=¿1.009–1.091; p¿=¿0.016). Receiver operating characteristic analysis showed that the area under curve of MDA serum levels to predict 30-day survival was 0.62 (95% CI¿=¿0.56–0.69; P¿=¿0.002). The risk of death in septic patients with MDA serum levels above 4.11 nmol/mL was higher than in patients with lower values (Hazard Ratio¿=¿2.43; 95% CI¿=¿1.49–3.94; p<0.001).
Conclusions:
The novel findings of our study on severe septic patients, to our knowledge the largest series providing data on the oxidative state, are that elevated MDA serum levels probably represent an unbalanced oxidant state and are related with poor prognosis in patients with severe sepsis.
000063300 536__ $$9info:eu-repo/grantAgreement/ES/ISCIII/FIS/PI10-01572$$9info:eu-repo/grantAgreement/ES/ISCIII/I3SNS-INT-11-063
000063300 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000063300 590__ $$a3.534$$b2013
000063300 591__ $$aMULTIDISCIPLINARY SCIENCES$$b8 / 56 = 0.143$$c2013$$dQ1$$eT1
000063300 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000063300 700__ $$aMartín, M.M.
000063300 700__ $$aAbreu-González, P.
000063300 700__ $$aDomínguez-Rodríguez, A.
000063300 700__ $$0(orcid)0000-0002-3312-9383$$aLabarta, L.$$uUniversidad de Zaragoza
000063300 700__ $$aDíaz, C.
000063300 700__ $$aSolé-Violán, J.
000063300 700__ $$aFerreres, J.
000063300 700__ $$aBorreguero-León, J.M.
000063300 700__ $$aJiménez, A.
000063300 700__ $$aMorera-Fumero, A.
000063300 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDepartamento de Medicina, Psiquiatría y Dermatología$$cMedicina
000063300 773__ $$g8, 1 (2013), e53741 [5 pp]$$pPLoS One$$tPLoS One$$x1932-6203
000063300 8564_ $$s208947$$uhttps://zaguan.unizar.es/record/63300/files/texto_completo.pdf$$yVersión publicada
000063300 8564_ $$s117830$$uhttps://zaguan.unizar.es/record/63300/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000063300 909CO $$ooai:zaguan.unizar.es:63300$$particulos$$pdriver
000063300 951__ $$a2017-11-28-12:46:03
000063300 980__ $$aARTICLE